IMTX
ImmaticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
Successful clinical readouts and a partnering deal validate the TCR approach, significantly derisking the pipeline and enabling re-rating toward mid-to-high teens per share; commercialization or buyout optionality could push value higher.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -3.4.
What can break
Clinical setbacks, slower-than-expected enrollment, or need for recurrent equity raises create dilution and downward re-rating; manufacturing or regulatory delays could keep shares under pressure.
Momentum
11
Value
41
Sentiment
71
Setup hits (3d)
— · Net —
AI TargetsBase $12.00 · Bull $18.00 · Bear $6.00
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2025-11-21 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net —
Target $18.26
Why
Momentum11 · Δ7d -5.1
Value41 · Δ7d -0.1
Sentiment71 · Δ7d -3.4
So what
Weak posture. Prioritize risk control and patience.
Lead driver: Sentiment · See AI snapshot
Momentum
11
26% active weight
Current posture
7d trendFlat
Δ7d
-5.1
Δ21d
-2.6
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
71
34% active weight
Current posture
7d trendSoftening
Δ7d
-3.4
Δ21d
-2.8
Why this grade
Composite grade D. Momentum 10.9 / Value 41.1 / Sentiment 70.6
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$1.29B
Beta
1.36
Shares Out
134.1M
P/E (TTM) · Derived
-5.3
P/S (TTM)
11.93
P/FCF (TTM) · Derived
-5.38
Rev YoY
-54.5%
EPS YoY
+45.6%
Gross Margin
-
Op Margin
-167.8%
Net Debt
-$532.85M
Current Ratio
8.78
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology